Patrick Cox visited the Shelton Facility on Dec. 11, 2015
December 17, 2015
Dear TransTech Reader,
Last week, I told you I was going to visit the NanoViricides (NNVC) production facility in Shelton, Connecticut. In fact, our CEO Ed D’Agostino and a cameraman also went, so we’ll have video for you in the near future.
The cGMP facility is impressive, as are the many world-class scientists who work there. It is, as far as I can tell, the only commercial nanoparticle production facility operating today. At the very least, it is certainly the only biotech nanoparticle production facility in existence. Pictures of the facility before completion and operation are available on the NanoViricides website here.
During my visit, I was able to talk with some of the scientists who are pioneering the mass production of the components needed to build the company’s virus-killing nanomachines. This facility is not large enough to manufacture sufficient Flucide to handle the enormous demand for an effective influenza medication, but it is big enough to make more than enough material for the upcoming toxicity studies. More important, it has the capacity to produce well over a billion dollars, by my calculation, of treatments for lower-volume higher-margin diseases such as ocular herpes.
I’m going to save additional specific information for another more in-depth report because proper presentation requires more time than I’ve had this week. This is partly due to the inconvenience of travel.
Eugene Seymour MD MPH
